Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata With or Without an Atopic Background From Two Randomized, Placebo-Controlled, Phase 3 Trials

    September 2022 in “ Journal of the American Academy of Dermatology ”
    Natasha Atanaskova Mesinkovska, Taisuke Ito, Maryanne M. Senna
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The document presents the results of two phase 3 trials (BRAVE-AA1 and BRAVE-AA2) involving 1200 patients with severe alopecia areata (AA), 37.8% of whom had an atopic background. The trials tested the efficacy and safety of baricitinib, a medication for AA. At week 36, 40.8% of patients with an atopic background who received 4-mg baricitinib achieved a Severity of Alopecia Tool (SALT) score ≤20, compared to 30.2% of those without an atopic background. Improvements in eyebrow/eyelash measures were also observed. The safety profile of baricitinib was similar in both subgroups and the overall population. The study concludes that the safety and improvements in hair regrowth in baricitinib-treated patients with severe AA were independent of atopic background.
    Discuss this study in the Community →